This study aimed to evaluate the efficacy of tertiary intravitreal administration of an anti-VEGF agent to treat a second ROP reactivation, to describe its effect on retinal vascularization promotion, and to assess possible risk factors indicating a poor prognosis following the third anti-VEGF therapy. Here, VEGFA is linked to retinopathy of prematurity.